Head and neck cancer DNA vaccine - Immune Cell Therapy

Drug Profile

Head and neck cancer DNA vaccine - Immune Cell Therapy

Alternative Names: IC-1002; IC-1002 personalised head and neck cancer vaccine; IC-1002 personalized head and neck cancer vaccine

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immune Cell Therapy
  • Class Cancer vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Head and neck cancer

Most Recent Events

  • 19 Sep 2017 Immune Cell Therapy and the University of Pittsburgh withdrawn a phase I trial for Head and neck cancer in USA prior to enrolment, before September 2017 (NCT02211027)
  • 16 Jul 2014 Preclinical trials in Head and neck cancer in USA (Intradermal)
  • 16 Jul 2014 Immune Cell Therapy and the University of Pittsburgh plan a phase I trial for Head and neck cancer in USA (NCT02211027)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top